

23rd Scientific Symposium of the Austrian Pharmacological Society

APHAR 2017

www.aphar.at



28–29 September 2017

INNSBRUCK

CCB, Campus Innrain



Photo CCB: © Innsbruck Tourismus


Organised by the Department of
Pharmacology and Toxicology,
University of Innsbruck, and the
Department of Pharmacology,
Medical University of Innsbruck

Location

CCB Center for Chemistry and Biomedicine

Campus Innrain, Innrain 80-82, A-6020 Innsbruck

Lecture Hall: L.EG.220 (Ground level)



Registration Fees and Organisation

| | |
|---------------------------|---|
| Registration Fee: | €50 APHAR members - €85 Non-members (Please pay the registration fee at the registration desk) Reduced registration fee for retired members of APHAR and for students <u>with written confirmation</u> of student status: € 25.- (The confirmation form can be downloaded from: http://www.aphar.at/2017 and should be signed by the head of the institution) Participation is free of charge for plenary speakers and for APHAR honorary members. |
| Travel Grants: | A limited number of travel grants (€ 200) are available for students of institutions outside Innsbruck. Please use the application form (http://www.aphar.at/2017) and return it at the registration desk of the meeting. Grants will be awarded in the order of their arrival. The grants were generously made available by AMGEN . |
| Registration Desk: | CCB Center for Chemistry and Biomedicine Innrain 80-82, A-6020 Innsbruck Opening hours: Thursday Sep 28: 08:30 – 12:00 Friday Sep 29: 09:00 – 10.00 |
| Language: | All presentations shall be given in English. |
| Organisation: | Austrian Pharmacological Society (APHAR) President: Thomas Griesbacher, Dept. Exp. & Clin. Pharmacology, Medical Univ. of Graz Tel: + 43 316 380-34610, Fax: +43 316 380-9645, thomas.griesbacher@medunigraz.at Secretary: Reiner Fischer-Colbrie, Department of Pharmacology, Innsbruck Medical University Tel: +43 512 9003-71220, Fax: +43 512 9003-73200, fischer-colbrie@i-med.ac.at |

9:00 Registration

10:00 Welcome address (Thomas Griesbacher, APHAR president)

Chair: Georg Wick (Innsbruck)

Plenary Lecture

10:15 Adrenal Steroid Hormones and the Cardiomyocyte: New Payers in Cardiovascular Health and Disease

✎ John A. CIDLOWSKI (Chief, Signal Transduction Lab, Natl. Inst. of Environmental Health Services, Research Triangle Park, NC, USA)

11:15 Coffee Break

Chair: Christoph Schwarzer (Innsbruck)

Short Communications 1

11:30 Evidence from FDM-TIRF microscopy for endothelial ER-PM junctions harboring the Na⁺/Ca²⁺ exchanger (NCX1) to serve privileged refilling of Ca²⁺ stores

A 1.3

✎ Cristiana M.L. DI GIURO, Niroj SHRESTHA, Sarah KRENN, Roland MALLI, Cornelis VAN BREEMEN, Nicola FAMELI and Klaus GROSCHNER (Graz, Vancouver)

11:45 The mechanisms of folding and trafficking of the human dopamine transporter (hDAT) and its disease-causing mutants

A 4.1

✎ Hafiz M.M. ASJAD, Ameya KASTURE, Ali EL-KASABY, Sonja SUCIC and Michael FREISSMUTH (Vienna)

12:15 Light-induced ganglion cell responses in Cav1.4-mutant mouse retinas

A 4.10

✎ Lucia ZANETTI, Hartwig SEITTER and Alexandra KOSCHAK (Innsbruck)

12:30 Role of monoamines in the mouse basolateral amygdala in the regulation of fear and anxiety

A 4.4

✎ Sara FERRAZZO, Claudia SCHMUCKERMAIR and Francesco FERRAGUTI (Innsbruck)

12:30 Lunch Break

12:30 Mitgliederversammlung der Sektion Klinische Pharmakologie

Members of the APHAR Section of Clinical Pharmacology only

Teilnahmeberechtigt sind alle Mitglieder der Sektion Klinische Pharmakologie der APHAR. Gemäß § 12 der Statuten wird den Sektionsmitgliedern die vorläufige Tagesordnung spätestens vier Wochen vor der Sektionsversammlung zugesandt. Gemäß § 3 der Geschäftsordnung der Sektion sind weitere Anträge zur Tagesordnung bis spätestens sieben Tage vor der Sektionsversammlung bei der Sektionsleitung schriftlich einzureichen.

Chair: Romuald Bellmann (*Innsbruck*)

Short Communications 2

- 14:30 **Pharmacokinetics of trimethoprim-sulfamethoxazole during continuous haemofiltration**
A 2.4 ↪ René WELTE, Johannes HOTTER, Tiziana GASPERETTI, Rudolph BEYER, Rosa BELLMANN-WEILER,
Stephan ESCHERTZHUBER, Marc-Michael ZARUBA, Ingo LORENZ, Mathias STRÖHLE, Michael JOANNIDIS
and Romuald BELLMANN (*Innsbruck*)
- 14:45 **Adverse drug reactions reported to the regional pharmacovigilance center Zurich in 2014–2016:
a retrospective, monocentre cohort study**
A 5.2 ↪ Luis GIOVANNONI, Gerd A. KULLAK-UBLICK and Stefan WEILER (*Zürich*)
- 15:00 **A proof-of-concept study to inhibit ABCB1- and ABCG2-mediated efflux transport at the human
blood–brain barrier**
X 4.5 ↪ Martin BAUER, Beatrix WULKERSDORFER, Rudolf KARCH, Cécile PHILIPPE, Eva-Maria KLEBERMASS, Lukas
NICS, Stefan POSCHNER, Walter JÄGER, Markus ZEITLINGER and Oliver LANGER (*Vienna, Seibersdorf*)
- 15:15 **Statin-associated immune-mediated necrotising myopathy: a retrospective study of WHO
pharmacovigilance safety reports**
A 5.3 ↪ Dirk K. ESSERS, Gerd A. KULLAK-UBLICK and Stefan WEILER (*Zürich*)

15:30 *Coffee Break*

15:45 *Interactive Poster Session (5 min presentations + 3 min discussion at poster)*

Chair: Eduard Stefan (*Innsbruck*)

Plenary Lecture

- 17:00 **Molecular and Structural Determinants of GPCR Functional Selectivity;
Impacts for Drug Discovery**
↪ Michel BOUVIER (*Dept. Biochemistry and Molecular Medicine, Faculty of Medicine, Univ.
de Montréal*)

18:00 *End of session*

18:00 GENERAL ASSEMBLY

Members of the Austrian Pharmacological Society only

Gem. § 9 der Statuten wird den Mitgliedern die vorläufige Tagesordnung spätestens vier Wochen vor der Generalversammlung zugeschickt. Weitere Anträge sind mindestens sieben Tage vor dem Termin der Versammlung beim Vorstand schriftlich einzureichen. Teilnahmeberechtigt sind alle ordentlichen Mitglieder, sowie Vertreter der außerordentlichen Mitglieder. Stimmberechtigt sind nur die ordentlichen Mitglieder.

19:30 APHAR Conference Dinner at Gasthof Bierstindl

don't miss the Stand-Up-Comedy-Magic-Show with Kalibo

Admittance for registered participants only. For further information see page 10.

Chair: Andrea Laslop (*Vienna*)

Plenary Lecture

08:30 Early access to medicines – adaptive pathways, accelerated approval and PRIME

↳ Tomas SALMONSEN (*Chair, CHMP EMA, London & Medicinal Products Agency, Uppsala, Sweden*)

09:30 Coffee Break

09:45 Interactive Poster Session (5 min presentations+ 3 min discussion at poster)

Chair: Sonja Susic (*Vienna*)

Short Communications 3

11:00 Partial releasers rescue misfolded serotonin transporters by conformational trapping

A 4.6 ↳ Shreyas BHAT, Peter S. HASENHUETL, Ameya KASTURE, Ali EL-KASABY, Michael H. BAUMANN, Bruce E. BLOUGH, Sonja SUSIC, Walter SANDTNER and Michael FREISSMUTH (*Vienna, Baltimore, Triangle Park*)

11:15 cAMP-initiated alterations of kinase interactions and conformations

X 3.1 ↳ Florian ENZLER, Dana J. STEFFEN, Leopold KREMSEK, Herbert H. LINDNER, Ulrich STELZL, J. Silvio GUTKIND and Eduard STEFAN (*Innsbruck, LaJolla*)

11:30 Does the pathology of multiple system atrophy manifest in the neuroretina?

X 4.12 ↳ Kathrin KAEHLER, Hartwig SEITTER, Adolf SANDBICHLER, Gerald J. OBERMAIR, Nadia STEFANOVA and Alexandra KOSCHAK (*Innsbruck*)

11:45 Effect and dynamics of nucleotides in the ABCB1 nucleotide binding domain dimer

X 3.6 ↳ Dániel SZÖLLÖSI and Thomas STOCKNER (*Vienna*)

12:00 End of session, Lunch break

Chair: Martin Brunner (*Vienna*)

Short Communications 4

13:00 Safety and efficacy of the C1s complement inhibitor TNT009 in a first-in-human trial

X 2.5 ↳ Johann BARTKO, Christian SCHÖRGENHOFER, Jim GILBERT, Sandip PANICKER, Shirley D'SA, Ulrich JÄGER and Bernd JILMA (*Vienna, San Francisco, London*)

13:15 The pharmacodynamic effects of rituximab at very low doses in healthy volunteers

A 2.1 ↳ Christian SCHÖRGENHOFER, Christa FIRBAS, Ulla DERHASCHNIG, Robert M. MADER, Raute SUNDER-PLABMANN, Petra JILMA-STOHLAWETZ, Kalpna DESAI, Priya MISRA, Ulrich JÄGER and Bernd JILMA (*Vienna, Toronto*)

13:30 Measurement of total retinal blood flow and oxygen extraction in patients with glaucoma

X 5.2 ↳ Ahmed M. BATA, Doreen SCHMIDL, Katarzyna J. WITKOWSKA, Klemens FONDI, Piotr A. WOZNAK, Stephan SZEGEDI, René M. WERKMEISTER, Gerhard GARHÖFER and Leopold SCHMETTERER (*Vienna, Singapore*)

13:45 Coffee Break

13:45 *Coffee Break*

Chair: Nadine Ortner (*Innsbruck*)

Short Communications 5

14:00 **Oligomerization of the human dopamine transporter**

X 4.1 ↻ Thomas STOCKNER, Kumaresan JAYARAMAN, Alexander N. MORLEY, Dániel SZÖLLŐSI, Tsjerk A. WASSENAAR and Harald H. SITTE (*Vienna*)

14:15 **Decoding kinase–GPCR interactions: dynamics of the macromolecular GPR161–PKA complex**

X 3.5 ↻ Johanna E. MAYRHOFER, Verena BACHMANN, Roger SUNAHARA, Susan TAYLOR and Eduard STEFAN (*Innsbruck, San Diego*)

14:30 **High fat diet induces imipramine-resistant depression-like phenotype**

X 4.15 ↻ Ahmed M. HASSAN, Marta OLIVARES, Audrey M. NEYRINCK, Nathalie M. DELZENNE, Florian REICHMANN, Geraldine ZENZ and Peter HOLZER (*Graz, Brussels*)

14:45 *End of session*

Chair: Thomas Griesbacher (*Graz*)

HERIBERT KONZETT & HANS HORST MEYER AWARDS 2017

14:45 The Hans Horst Meyer Award of the Austrian Pharmacological Society is awarded to young investigators in experimental and clinical pharmacology and toxicology.

Donated by  Austria Corporation.



H.H. Meyer
1853 – 1939

The Heribert Konzett Award of the Austrian Pharmacological Society is awarded to young investigators in experimental and clinical pharmacology in recognition of their independent research achievements.

Donated by  Austria.



H. Konzett
1912 – 2004

↻incl. Lecture *Heribert Konzett Laureate*

15:30 *End of meeting (train to Vienna: 16:17, 17:14; train to Graz: 16:17)*

Poster Presentations

Dimensions of the poster boards: A0 vertical. Posters will be on display for the entire period of the meeting (Thursday and Friday). Presenting authors are requested to present their poster in interactive sessions (5 min presentations + 3 min discussion) on Thursday (session 1–3 from 15.45–17.00) and on Friday (sessions 4–6 from 9.45–11.00).

Session 1

- A 1.1 **Bioactivation of simvastatin by probiotic bacteria: in vitro study**
↳ MAJA ĐANIĆ, SAŠA VUKMIROVIĆ, NEBOJŠA PAVLOVIĆ, BOJAN STANIMIROV, SVETLANA GOLOČORBIN-KON and MOMIR MIKOV (NOVI SAD)
- A 2.2 **Lysophospholipid-enriched HDL suppresses platelet activation**
↳ Sanja ČURČIĆ, Michael HOLZER, Lisa PASTERK, Eva KNUPLEŽ, Thomas O. EICHMANN, Saša FRANK, Robert ZIMMERMANN, Rudolf SCHICHO, Ákos HEINEMANN and Gunther MARSCHÉ (Graz)
- A 4.3 **KV7 and TRPV1 channels: neuronal targets for the analgesic action of paracetamol**
↳ Sutirtha RAY, Isabella SALZER and Stefan BOEHM (Vienna)
- A 4.8 **Different neuronal activation patterns in different amygdala nuclei after fasting and fear extinction**
↳ Lucas B. COMERAS, Birgit HÖRMER, Elisabeth GASSER and Ramon O. TASAN (Innsbruck)
- X 3.3 **Kinase regulation of the TAF15 molecular interactions**
↳ Omar TORRES-QUESADA, Christoph SCHNEIDER, Elisabeth FUCHS, Herbert H. LINDNER, Ronald MICURA and Eduard STEFAN (Innsbruck)
- X 4.10 **A Cav1.3 L-type Ca²⁺ channel splice variant is activating at more hyperpolarized potentials**
↳ Nadja HOFER, Alexandra PINGGERA, Nadine J. ORTNER and Jörg STRIESSNIG (Innsbruck)
- X 5.1 **Effect of single instillation of lipid emulsion eye drops on interferometric tear film lipid layer thickness measurements in healthy volunteers**
↳ Stephan SZEGEDI, Ahmed BATA, Klemens FONDI, Ulrike SCHESCHY, Doreen SCHMIDL, Valentin ARANHA DOS SANTOS, Alina MESSNER, Hannes STEGMANN, René M. WERKMEISTER, Leopold SCHMETTERER and Gerhard GARHÖFER (Vienna)

Session 2

- A 1.2 **The association of NT-proBNP and asymmetrical dimethylarginine with all-cause mortality in long-term geriatric care patients**
↳ Safoura SHEIKH REZAEI, Stefan WEISSHAAR, Brigitte LITSCHAUER, Ghazaleh GOUYA, Michael WOLZT and Gerald OHRENBERGER (Vienna)
- A 4.9 **Neuropeptide Y and Y₂ receptors in hippocampus-dependent fear and spatial learning**
↳ Birgit A. HÖRMER, Dilip VERMA, Elisabeth GASSER, Herbert HERZOG and Ramon O. TASAN (Innsbruck, Sydney)
- A 7.1 **Pharmacological and molecular modeling studies on 6-desoxo-N-methylmorphinans as potent agonists interacting with the μ-opioid receptor**
↳ Maria DUMITRASCUTA, Tanila BEN HADDOU, Elena GUERRIERI, Stefan M. NOHA, Helmut SCHMIDHAMMER and Mariana SPETEA (Innsbruck)
- X 2.3 **Imatinib inhibits TNF-α via PGE₂ and the EP₄ receptor**
↳ Thomas BÄRNTHALER, Katharina JANDL, Rudolf SCHICHO, Barbara UHL, Florian REICHMANN, Magdalena GRILL, Gunther MARSCHÉ, Heinz SILL, Ákos HEINEMAN¹ and Rufina SCHULIGOI (Graz)

Poster Presentations

X 4.4 **The N-terminus specifies the switch between transport modes of the human serotonin transporter**
↳ Carina KERN, Fatma Asli ERDEM, Ali EL-KASABY, Walter SANDTNER, Michael FREISSMUTH and Sonja SUCIC (Vienna)

X 4.14 **Rewiring of bipolar cells in mouse models of congenital stationary night blindness type 2**
↳ İrem KILIÇARSLAN, Hartwig SEITTER, Enrica STRETTOI and Alexandra KOSCHAK (Innsbruck, Pisa)

Session 3

A 2.3 **Dose optimization of antibacterials: plasma vs. tissue concentrations**
↳ Ana TOMAS, Zdenko TOMIĆ, Nebojša STILINOVIĆ, Olga HORVAT, Milica PAUT KUSTURICA, Bojan STANIMIROV and Ana SABO (Novi Sad)

A 3.1 **Identification and characterization of the Fasciola hepatica taurine transporter**
↳ Bulut HAMALI, Sandra PICHLER, Melanie BURGER, Oliver KUDLACEK and Michael FREISSMUTH (Vienna)

A 4.7 **Nuclear effectors of oncogenic BRAF signaling and their pharmacological inhibition**
↳ Andreas FEICHTNER, Kane PUGLISI, Eduard STEFAN and Markus HARTL (Innsbruck)

A 4.11 **Functional neuroanatomy of prodynorphin**
↳ Iwona KMIEĆ, Mario MIETZSCH, Luca ZAGRANDE, Lill ANDERSON, Thomas RÜLICHE, Regine HEILBRONN and Christoph SCHWARZER (Innsbruck, Berlin, Vienna)

A 6.1 **Recognition and training of medical specialists in (Clinical) Pharmacology in Europe: a pilot survey of the UEMS Section of Pharmacology**
↳ Thomas GRIESBACHER (Graz)

X 2.4 **Pharmacokinetics of temocillin in healthy subjects after intravenous and subcutaneous dosing**
↳ Peter MATZNELLER, Perrin NGOUGNI POKEM, Arnaud CAPRON, Françoise Van BAMBEKE and Markus ZEITLINGER (Vienna, Brussels)

X 4.8 **Microglial alterations in a mouse model of innate anxiety and depression**
↳ Sinéad ROONEY, Anupam SAH, Susanne A. WOLF, Simone B. SARTORI, Christoph SCHWARZER, Helmut KETTENMANN and Nicolas SINGEWALD (Innsbruck, Berlin)

Session 4

A 2.6 **Impact of erythrocytes and thrombocytes on bacterial growth and antimicrobial activity of selected antibiotics**
ALINA K. NUSSBAUMER-PRÖLL, SOPHIE KNOTZER, SABINE EBERL AND MARKUS ZEITLINGER (VIENNA)

A 5.1 **Prescription of antibiotics for systemic use in Austria, 2006–2014**
↳ Georg WIETZORREK (Innsbruck)

X 2.2 **Role of high-density lipoprotein (HDL) composition and function in allergy**
↳ Athina TRAKAKI, Eva STURM, Gunter STURM, Sabine MEISSL, Ákos HEINEMANN and Gunther MARSCHKE (Graz)

X 3.4 **Surveillance of drug-driven BRAF conformations and interactions**
↳ Ruth RÖCK, Johanna E. MAYRHOFER, Andrea RAFFEINER, Philipp RAFFEINER, Florian ENZLER, Roland HUBER, Susan S. TAYLOR, Jakob TROPFMAIR and Eduard STEFAN (Innsbruck, Singapore, San Diego)

X 4.3 **Interaction of transcription factor T-brain-1 with Cav1.3 L-type calcium channels**
↳ Anita SILLER, Andrea RAFFEINER, Vera KRÖLL, Alexandra PINGGERA, Marta CAMPIGLIO, Eduard STEFAN and Jörg STRIESSNIG (Innsbruck, Cambridge)

X 4.9 **Investigating the second ion lock of the human dopamine transporter *in silico* and *in vitro***
↳ Alexander MORLEY, Yang LI, Felix P. MAYER, Walter SANDTNER, Harald H. SITTE and Thomas STOCKNER (Vienna)

Poster Presentations


Session 5

- A 4.2 **129S1/SvlmJ mouse model of impaired fear extinction shows abnormal sleep architecture**
↳ *Eva Maria FRITZ, Matthias KREUZER, Nigel WHITTLE, Nicolas SINGEWALD and Thomas FENZL (Innsbruck, Atlanta, Basel)*
- A 4.5 **The selective κ -opioid receptor partial agonist HS666 produces antinociceptive, antiseizure and anticonvulsant effects without causing sedation or motor dysfunction after systemic administration in mice**
↳ *Filippo ERLI, Alexandra AGOSTINHO, Helmut SCHMIDHAMMER, Christoph SCHWARZER and Mariana SPETEA (Innsbruck)*
- X 1.1 **The unique characteristics of segment IS4 in voltage-gated calcium channel Cav1.2 inactivation**
↳ *Stanislav ANDRANOVITŠ, Stanislav BEYL, Annette HOHAUS, Eva-Maria ZANGERL-PLESSL, Eugen TIMIN and Steffen HERING (Vienna)*
- X 3.2 **Colon cancer cells attract and activate eosinophils**
↳ *Carina HASENOEHL, Julia HORVATH, Eva STURM and Rudolf SCHICHO (Graz)*
- X 4.7 **Conformations and oligomeric interfaces of human dopamine transporter**
↳ *Kumaresan JAYARAMAN, Alexander N. MORLEY, Dániel SZÖLLÖSI, Tsjerk A. WASSENAAR, Harald H. SITTE and Thomas STOCKNER (Vienna, Groningen)*
- X 4.13 **Role of the dopamine system in deficient fear extinction using a PTSD mouse model**
↳ *Thomas M. V. KEIL, Simone B. SARTORI, Karl EBNER and Nicolas SINGEWALD (Innsbruck)*

Session 6

- A 2.5 **Quantification of the antifungal anidulafungin in human brain tissue**
↳ *Jana MARX, René WELTE, Patrizia MOSER and Romuald BELLMANN (Innsbruck)*
- A 3.2 **Hepatoprotective and antioxidant potential of apigenin in paracetamol-induced hepatotoxicity in rats**
↳ *Nikola MARTIĆ, Aleksandar RAŠKOVIĆ, Boris MILIJAŠEVIĆ, Slobodan GIGOV, Ivan ČAPO, Milica PAUT KUSTURICA and Sunčica KOJIĆ DAMJANOV (Novi Sad)*
- X 2.1 **The role of lysophosphatidylcholine in eosinophil activation**
↳ *Eva KNUPLEŽ, Sanja ČURČIĆ, Ákos HEINEMANN and Gunther MARSCHKE (Graz)*
- X 4.2 **Lower affinity of isradipine for L-type Ca^{2+} channels during substantia nigra dopamine neuron-like activity: implications for neuroprotection in Parkinson's disease**
↳ *Nadine J. ORTNER, Gabriella BOCK, Antonios DOUGALIS, Maria KHARITONOVA, Johanna DUDA, Simon HESS, Petronel TULUC, Thomas POMBERGER, Nadia STEFANOVA, Florian PITTLERL, Thomas CIOSEK, Herbert OBERACHER, Henning J. DRAHEIM, Peter KLOPPENBURG, Birgit LISS and Jörg STRIESSNIG (Innsbruck, Ulm, Köln, Biberach)*
- X 4.6 **Role of the PACAP/PAC₁ receptor system within forebrain areas in modulation of behavioral and neuroendocrine stress reactions**
↳ *Veronica FONTEBASSO, Nicolas SINGEWALD and Karl EBNER (Innsbruck)*
- X 4.11 **Characterization of novel dopamine transporter inhibitor CE-123: synthesis and stereoselective inhibitory effect**
↳ *Marija ILIĆ, Predrag KALABA, Vladimir DRAGAČEVIĆ, Nilima Y. AHER, Johann LEBAN, Ernst URBAN, Thierry LANGER, Gert LUBEC and Harald H. SITTE (Vienna, Innsbruck, Bratislava)*
- X 4.16 **Retinal frequency-dependent responses are delayed in a mouse model of multiple system atrophy**
↳ *Hartwig SEITTER, Nadja STEFANOVA and Alexandra KOSCHAK (Innsbruck)*

APHAR Conference Dinner (Gasthof Bierstindl)



Admittance
for registered
participants only

Thursday 28 Sept

Time: 19:30

Stand-Up-
Comedy-Magic-
Show
with Kalibo

Kulturgasthaus Bierstindl, Klostersgasse 6, 6020 Innsbruck, Tel: 0512-58000-0.

25 min walk or tram 1 to the final station Bergisel

Austrian Pharmacological Society (APHAR):

Executive Committee:

President: Thomas Griesbacher (Graz), Vice-President: Jörg Striessnig (Innsbruck), Secretary: Reiner Fischer-Colbrie (Innsbruck), Treasurer: Michael Pohl (Vienna), Chair of the Section of Clinical Pharmacology: Markus Zeitlinger (Vienna), Further Member of the Executive Committee: Alexandra Koschak (Vienna).

Clinical Pharmacology Section Committee:

Chair: Markus Zeitlinger (Vienna), Vice-Chair: Martin Brunner (Vienna), Further Member of the Section Committee: Romuald Bellmann (Innsbruck).

ZVR-Zahl: 202359700 Website: <http://www.aphar.at/>

Supporting Members of APHAR:

